Carmen Alcalá

1.2k total citations · 1 hit paper
23 papers, 743 citations indexed

About

Carmen Alcalá is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Carmen Alcalá has authored 23 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 11 papers in Neurology and 7 papers in Oncology. Recurrent topics in Carmen Alcalá's work include Multiple Sclerosis Research Studies (16 papers), Peripheral Neuropathies and Disorders (9 papers) and Polyomavirus and related diseases (6 papers). Carmen Alcalá is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Peripheral Neuropathies and Disorders (9 papers) and Polyomavirus and related diseases (6 papers). Carmen Alcalá collaborates with scholars based in Spain, United States and Germany. Carmen Alcalá's co-authors include Bonaventura Casanova, Francisco Pérez‐Miralles, Sara Gil‐Perotín, Francisco Gascón, Eugenia Martínez‐Hernández, Maarten J. Titulaer, Tania Cellucci, Warren Mason, Mar Petit‐Pedrol and Josep Dalmau and has published in prestigious journals such as The Lancet Neurology, Frontiers in Immunology and Journal of the Neurological Sciences.

In The Last Decade

Carmen Alcalá

22 papers receiving 727 citations

Hit Papers

Encephalitis with refractory seizures, status epilepticus... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies
    2014 404 citations Mar Petit‐Pedrol, Thaís Armangué et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carmen Alcalá Spain 11 481 252 148 105 98 23 743
Adrian Budhram Canada 15 755 1.6× 298 1.2× 183 1.2× 65 0.6× 84 0.9× 85 971
Pavel Štourač Czechia 14 229 0.5× 233 0.9× 120 0.8× 104 1.0× 51 0.5× 54 645
Amy Kunchok United States 16 807 1.7× 517 2.1× 137 0.9× 93 0.9× 52 0.5× 47 1.0k
Amy May Lin Quek United States 9 865 1.8× 317 1.3× 217 1.5× 39 0.4× 149 1.5× 14 1.0k
Leslie Benson United States 12 650 1.4× 585 2.3× 86 0.6× 58 0.6× 50 0.5× 23 964
Anna R. Tröscher Austria 10 148 0.3× 232 0.9× 160 1.1× 69 0.7× 30 0.3× 14 667
Gülşen Akman‐Demir Türkiye 25 754 1.6× 501 2.0× 198 1.3× 59 0.6× 63 0.6× 49 1.6k
Gregorio Spagni Italy 14 528 1.1× 168 0.7× 109 0.7× 91 0.9× 40 0.4× 33 708
Mark Woodhall United Kingdom 10 937 1.9× 854 3.4× 131 0.9× 87 0.8× 59 0.6× 14 1.2k
Hacer Durmuş Türkiye 15 327 0.7× 63 0.3× 183 1.2× 37 0.4× 72 0.7× 49 594

Countries citing papers authored by Carmen Alcalá

Since Specialization
Citations

This map shows the geographic impact of Carmen Alcalá's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Alcalá with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Alcalá more than expected).

Fields of papers citing papers by Carmen Alcalá

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Alcalá. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Alcalá. The network helps show where Carmen Alcalá may publish in the future.

Co-authorship network of co-authors of Carmen Alcalá

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Alcalá. A scholar is included among the top collaborators of Carmen Alcalá based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Alcalá. Carmen Alcalá is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Contreras, F., Guillermo Sánchez, Pedro Ramos, et al.. (2023). Clinical Outcomes and Prognostic Factors of Patients With Early Malignant Melanoma in One Latin American Country: Results of the Epidemiological Registry of Malignant Melanoma in Colombia Study. JCO Global Oncology. 9(9). e2200377–e2200377. 1 indexed citations
3.
Cubas-Núñez, Laura, et al.. (2023). Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?. Multiple Sclerosis and Related Disorders. 79. 105033–105033. 1 indexed citations
4.
Pérez‐Miralles, Francisco, et al.. (2023). Eculizumab for a catastrophic relapse in NMOSD: case report. Neurological Sciences. 45(1). 249–251. 5 indexed citations
5.
Gil‐Perotín, Sara, Laura Cubas-Núñez, Carmen Alcalá, et al.. (2022). High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis. Frontiers in Immunology. 13. 827738–827738. 17 indexed citations
6.
Gascón, Francisco, et al.. (2022). Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series. Frontiers in Neurology. 13. 897275–897275. 9 indexed citations
7.
Alcalá, Carmen, Francisco Gascón, Ángel Pérez Sempere, et al.. (2022). Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study. Journal of Neurology. 269(7). 3676–3681. 12 indexed citations
8.
Casanova, Bonaventura, José Ignacio Fernández-Velasco, Carmen Alcalá, et al.. (2022). Oligoclonal M bands unveil occult inflammation in multiple sclerosis. Multiple Sclerosis and Related Disorders. 68. 104118–104118. 5 indexed citations
9.
Pérez‐Miralles, Francisco, et al.. (2021). Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis. European Neurology. 85(2). 112–121. 8 indexed citations
10.
Alcalá, Carmen, Jaime Ferrer-Lozano, Nico Melzer, et al.. (2020). An expanded parenchymal CD8+ T cell clone in GABAA receptor encephalitis. Annals of Clinical and Translational Neurology. 7(2). 239–244. 13 indexed citations
11.
Pérez‐Miralles, Francisco, et al.. (2020). Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks. Acta Neurologica Belgica. 121(6). 1767–1775. 2 indexed citations
12.
Pérez‐Miralles, Francisco, et al.. (2020). Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks. Journal of the Neurological Sciences. 419. 117180–117180. 5 indexed citations
13.
Gil‐Perotín, Sara, Laura Cubas-Núñez, David Hervás, et al.. (2019). Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Frontiers in Neurology. 10. 1008–1008. 61 indexed citations
14.
Casanova, Bonaventura, Francisco Gascón, David Hervás, et al.. (2018). Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients. Neurological Sciences. 39(8). 1423–1430. 5 indexed citations
15.
Coret, Francisco, Francisco Pérez‐Miralles, Francisco Gascón, et al.. (2018). Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Multiple Sclerosis Journal - Experimental Translational and Clinical. 4(2). 2453203315–2453203315. 26 indexed citations
16.
Alcalá, Carmen, et al.. (2018). Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease. Multiple Sclerosis and Related Disorders. 27. 406–408. 17 indexed citations
17.
Alcalá, Carmen, Francisco Gascón, Francisco Pérez‐Miralles, et al.. (2018). Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. Journal of Neurology. 265(7). 1690–1697. 47 indexed citations
18.
Casanova, Bonaventura, Isidro Jarque, Francisco Gascón, et al.. (2017). Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurological Sciences. 38(7). 1213–1221. 40 indexed citations
19.
Petit‐Pedrol, Mar, Thaís Armangué, Xiaoyu Peng, et al.. (2014). Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. The Lancet Neurology. 13(3). 276–286. 404 indexed citations breakdown →
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adrian Budhram Breakdown of academic impact, for papers by Pavel Štourač Breakdown of academic impact, for papers by Amy Kunchok Breakdown of academic impact, for papers by Amy May Lin Quek Breakdown of academic impact, for papers by Leslie Benson Breakdown of academic impact, for papers by Anna R. Tröscher Breakdown of academic impact, for papers by Gülşen Akman‐Demir Breakdown of academic impact, for papers by Gregorio Spagni Breakdown of academic impact, for papers by Mark Woodhall Breakdown of academic impact, for papers by Hacer Durmuş
Rankless by CCL
2026